Science rarely fails on the merits. It fails in the moments when everything has to come together at once and there is no time to assemble a team. Those are the moments we are built for.
When a readout is ninety days out, when a raise hinges on a story, when a discovery has to become something the world can grasp, you do not need a vendor for each piece. You need one transdisciplinary team, briefed together and moving as a unit: PhD science writers, certified medical illustrators and animators, brand strategists, and web, in one room, on one deadline.
Inflection points, where the story a company tells decides what happens next.
The science is real and the name is chosen. Everything else that tells the world who you are is still a blank page, and the first identity you put forward shapes how investors, recruits, and partners read you before you say a word.
This is where scientific literacy and brand strategy have to be one conversation. We find the metaphor that makes your science legible, then build the naming, identity, and system around it.
How a circular genome became Ring Therapeutics’ mark →A raise or a partnership hinges on a story a non-specialist can evaluate quickly, while attention is finite and the narrative is being priced in real time. The science has to be legible without being flattened.
We build the value proposition, the narrative, and the visuals that carry it, from the SVP through the deck, so the case holds together under diligence.
Sana: the platform diagrams behind its S-1 and investor engagements →The science moved, or the market did, and the story you have no longer fits the company you are becoming. A pivot has to keep the equity you have earned while making room for where you are headed.
We assess what your current brand carries and what it does not, then evolve the strategy, language, and system so the new direction reads as a deliberate choice.
Carena: evolving a brand to lead in virtual care →You are ninety days from a number. When it lands it can reprice the company, and you get one chance to frame what it means before the market frames it for you.
The science, the investor narrative, the data visualization, and the release choreography have to move as one object under a deadline that does not move. That is the team we field.
TriSalus: visualizing clinical data, mechanism, and patient outcomes →The science is mature. Now it has to perform in front of investors, regulators, clinicians, and patients at the same time, each of whom needs a different version of the truth with no contradiction between them.
We build the brand, the education, and the field-facing assets from a single narrative spine, so every audience meets a story calibrated to what they need.
Kartos & Telios: a congress debut that reached clinicians, investors, and patients at once →The brand has outgrown its origins. Teams, pipeline, and audiences have multiplied, and a system built for a smaller company is straining to hold them together.
We build design systems and brand architecture that give a larger organization consistency without flattening it, and we bring the science into the spaces where culture is built.
Cytokinetics: activating brand and science across a new building, floor by floor →The moments when science has to reach beyond the company that made it, to a field, a policy, a public.
A genuine breakthrough is often illegible to everyone outside the lab that made it. Its significance has to be made visible before it can earn the belief, capital, and partners it deserves.
We deconstruct the science to its essentials with our writers and illustrators, then rebuild it into a narrative and visuals that make the discovery land for specialists and generalists alike.
Moderna: visualizing mRNA as a new class of medicine, from R&D days to the TED stage →An approval, a label, or a policy position carries consequences measured in patients and years. Precision is not optional, and the line between education and promotion has to be respected exactly.
We write and design for regulated moments with medical, legal, and regulatory review built in, grounded in FDA AdPromo training. This work spans pharma and the One Health and public-health policy arenas.
Regulatory and clinical communications →Proof link is a placeholder. A regulatory and One Health case note is being sourced.
A crisis brings a firehose of information and a narrow window to make it trustworthy. People need to know what is happening and what to do, faster than the evidence settles.
We synthesize credible sources into clear science and data visualization and keep updating as the picture changes, so a fast-moving situation stays legible without losing nuance.
The COVID-19 case study we published, updated 148 times, with figures used in Nature and by institutions worldwide →Disease awareness, advocacy, and knowledge translation succeed only when they change what people understand and do. Information alone moves no one.
We ground the work in behavioral and cognitive principles and build it with the audience rather than only for them, so the science becomes something people can act on.
Project UnLonely, and equitable self-test guides now used in 22 languages →That is often the first thing worth talking through. Tell us where you are, and we will be straight about where we can help and where another partner would serve you better.